Mintz Venture Watch — Volume 2: A Report on Deal Trends from Q3 and Q4 2021

By Daniel I. DeWolf, Lewis J. Geffen, Jeremy D. Glaser

65+

Transactions

  

$2.3B

Deal Value

  

7

Industries

 
Venture capital investing continues to thrive across all sectors. During the first half of 2021, the Mintz team advised more than 65 emerging companies and investors in transactions in all facets of the life sciences, technology, and energy and sustainability industries.

Fintech

Mintz advised T-REX Group, a fintech company that has developed a SaaS platform to more accurately and efficiently value securities in complex asset classes, including alternative energy, in an initial close of a $40 million Series C financing. T-REX was founded to address two distinct gaps in the market: the absence of modern technology to power complex asset finance and the need for tools to accelerate investment into energy transition. This financing will facilitate transformational change in sustainable infrastructure investment and capital markets more broadly.

Life Sciences

Mintz advised Cardurion Pharmaceuticals, Inc., a clinical-stage biotechnology company, in a recently closed private investment of up to $300 million from Bain Capital Life Sciences and Bain Capital Private Equity. Bain Capital joins existing investors Takeda Pharmaceuticals and Polaris Partners in supporting the evolution of Cardurion into a leading cardiovascular biotechnology company. This latest investment will support the thoughtful advancement of Cardurion’s pipeline, enabling the company to scale its team and create an industry-leading platform.

Technology

Gluware, a company rich in IP assets, raised $35 million from Bain Capital Credit using a new financing alternative called IP-backed debt. Mintz advised Gluware, Inc. in this innovative fundraising transaction that closed in October 2021. These IP-backed loans provide significant growth capital to companies that are normally shut out of the debt financing markets.

You can also ask us anything at http://mintzedge.com/ask-anything/. We built the MintzEdge website as a resource for entrepreneurs and investors, and hope that all of you take advantage of the site and see how it can help you.

 Juristat Top Patent Firm

Subscribe To Viewpoints

Published

    • Viewpoint Topics

  • Venture Capital & Emerging Companies
  • Technology

    • Professionals

  • Daniel I. DeWolf
  • Lewis J. Geffen
  • Jeremy D. Glaser

    • Related Practices

  • Venture Capital & Emerging Companies

    • Related Industries

  • Technology
    • Technology Viewpoints Thumbnail

    Mintz Venture Watch — Volume 1: A Report on Deal Trends from Q1 and Q2 2021

    August 10, 2021| Article|

    Authors

    Daniel I. DeWolf

    Member / Chair, Technology Practice; Co-chair, Venture Capital & Emerging Companies Practice

    Daniel I. DeWolf is an authority on growth companies and serves as Chair of Mintz's Technology Practice Group and Co-chair of the firm’s Venture Capital & Emerging Companies Practice. He has worked on pioneering online capital-raising methods. He also teaches venture capital law at NYU Law School.

    Lewis J. Geffen

    Member / Co-chair, Life Sciences Practice

    Lewis J. Geffen is a corporate and licensing attorney at Mintz who helps companies manage strategic issues and complex transactions. Lewis provides financing and licensing guidance to biotechnology, pharmaceutical, medical device, and MedTech companies.

    Jeremy D. Glaser

    Member / Co-chair, Venture Capital & Emerging Companies Practice

    Jeremy D. Glaser is Co-chair of Mintz's Venture Capital & Emerging Companies Practice. He has over three decades of experience guiding life sciences and technology companies in growth and financing strategies, including public offerings, financings, mergers and acquisitions, and SEC compliance.